Is Karyopharm Therapeutics, Inc. overvalued or undervalued?

As of 15 March 2018, Karyopharm Therapeutics, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of -0.19, an EV to EBIT of -1.25, and an EV to EBITDA of -1.26, indicating significant financial distress and negative capital employed.
When compared to peers, Karyopharm's P/E ratio of -0.3521 is notably less favorable than Zevra Therapeutics, Inc. at -5.0550 and Emergent BioSolutions, Inc. at -4.1339. The overall peer comparison suggests that Karyopharm is underperforming relative to its industry counterparts. Additionally, the company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -57.32% compared to the index's 2.44%, reinforcing the notion that Karyopharm is currently overvalued.